The potential rescheduling of cannabinoids, particularly at the federal level, is generating considerable anticipation within the sector. A shift away from Schedule I status, often regarded as outdated and hindering innovation, could unlock significant possibilities for businesses. Reduced regulatory restrictions, alongside greater access to bankin